Literature DB >> 32139148

Significance of the number of high-risk factors in patients with cervical cancer treated with radical hysterectomy and concurrent chemoradiotherapy.

Hakyoung Kim1, Won Kyung Cho2, Yeon Joo Kim3, Young Seok Kim4, Won Park5.   

Abstract

OBJECTIVE: The purpose of this study was to evaluate the impact of high-risk factors on the survival of patients with cervical cancer treated with surgery followed by adjuvant chemoradiotherapy.
METHODS: From 2000 to 2014, medical records of 897 patients with International Federation of Gynecology and Obstetrics stage IB-IIA disease treated with surgery were retrospectively reviewed. Among them, 483 patients with high-risk factors, including pelvic lymph node metastasis, parametrial invasion, or resection margin involvement, were analyzed.
RESULTS: The median follow-up time was 57 months (range, 6-205 months). For patients with single and multiple high-risk factors, the 5-year DFS rates were 80.4% and 65.7%, respectively (p < 0.001), and 5-year OS rates were 87.3% and 75.1%, respectively (p = 0.001). Distant metastasis was the most common pattern of recurrence (86.1%). Furthermore, distant metastasis-free survival significantly differed with the number of high-risk factors present (single 82.7% vs. multiple 68.8%, p < 0.001). In the multivariate analysis, while parametrial invasion and resection margin involvement showed no association, the adenocarcinoma histology, pelvic lymph node metastasis, higher metastatic lymph node ratio, and multiple high-risk factors were independent prognosticators associated with poor DFS and OS.
CONCLUSIONS: Patients with early-stage cervical cancer having multiple high-risk factors, adenocarcinoma histologic type, and pelvic lymph node metastasis accompanied by a higher lymph node ratio after surgery are more likely to have occult distant metastasis. Further, consolidation with systemic chemotherapy after adjuvant therapy might be considered to improve the survival outcome in this patient population.
Copyright © 2020. Published by Elsevier Inc.

Entities:  

Keywords:  Adjuvant radiotherapy; Cervical cancer; Risk factor; Survival analysis

Year:  2020        PMID: 32139148     DOI: 10.1016/j.ygyno.2020.02.031

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  7 in total

1.  Diagnostic Strategies for Recurrent Cervical Cancer: A Cohort Study.

Authors:  Xiaopei Chao; Junning Fan; Xiaochen Song; Yan You; Huanwen Wu; Ming Wu; Lei Li
Journal:  Front Oncol       Date:  2020-12-07       Impact factor: 6.244

2.  Nomogram Predicting Overall Survival in Patients with FIGO II to III Squamous Cell Cervical Carcinoma Under Radical Radiotherapy: A Retrospective Analysis Based on 2018 FIGO Staging.

Authors:  Lele Zang; Qin Chen; Xiaozhen Zhang; Xiaohong Zhong; Jian Chen; Yi Fang; An Lin; Min Wang
Journal:  Cancer Manag Res       Date:  2021-12-29       Impact factor: 3.989

3.  The Combination of T Stage and the Number of Pathologic Lymph Nodes Provides Better Prognostic Discrimination in Early-Stage Cervical Cancer With Lymph Node Involvement.

Authors:  Yongrui Bai; Ling Rong; Bin Hu; Xiumei Ma; Jiahui Wang; Haiyan Chen
Journal:  Front Oncol       Date:  2021-11-05       Impact factor: 6.244

4.  Clinical Implication of Simultaneous Intensity-modulated Radiotherapy Boost to Tumor Bed for Cervical Cancer with Full-thickness Stromal Invasion.

Authors:  Zongkai Zhang; Long Jiang; Rui Bi; Xiaohua Wu; Jun Zhu; Guihao Ke
Journal:  Oncologist       Date:  2022-02-03

5.  Long non-coding RNA KCNQ1OT1 facilitates the progression of cervical cancer and tumor growth through modulating miR-296-5p/HYOU1 axis.

Authors:  Jun Liu; Yingmei Wang
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

6.  Effect of Number of Retrieved Lymph Nodes on Prognosis in FIGO Stage IA1-IIA2 Cervical Cancer Patients Treated With Primary Radical Surgery.

Authors:  Shan Jiang; Peng Jiang; Tingting Jiang; Yuan Tu; Jingni Zhang; Ning Li; Wei Kong; Yuzhen Huang; Rui Yuan
Journal:  Clin Med Insights Oncol       Date:  2022-09-30

7.  Should the Number of Metastatic Pelvic Lymph Nodes be Integrated into the 2018 Figo Staging Classification of Early Stage Cervical Cancer?

Authors:  Luigi Pedone Anchora; Vittoria Carbone; Valerio Gallotta; Francesco Fanfani; Francesco Cosentino; Luigi Carlo Turco; Camilla Fedele; Nicolò Bizzarri; Giovanni Scambia; Gabriella Ferrandina
Journal:  Cancers (Basel)       Date:  2020-06-12       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.